Exclusion Criteria:~* Does not have a reliable caregiver who is in frequent contact with the participant
(defined as at least 10 hours per week), will accompany the participant to the office and/or be available by
telephone at designated times, and will monitor administration of prescribed medications~* Meets National
Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement
en Neurosciences (NINDS/AIREN) criteria for vascular dementia~* Has current serious or unstable illnesses
including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other
than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's
opinion, could interfere with the analyses of safety and efficacy in this study; or has a life expectancy of <2
years~* Has had a history within the last 5 years of a serious infectious disease affecting the brain or head
trauma resulting in protracted loss of consciousness~* Has a history within the last 5 years of a primary or
recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal
cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen
posttreatment~* Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or
severe drug allergies, or severe posttreatment hypersensitivity reactions~* Has received acetylcholinesterase
inhibitor (AChEIs), memantine and/or other AD therapy for less than 4 months or has less than 2 months of
stable therapy on these treatments~* Has received medications that affect the central nervous system (CNS),
except treatments for AD, for less than 4 weeks~* Has a history of chronic alcohol or drug abuse/dependence
within the past 5 years~* Has a Visit 1 MRI with results showing >4 Amyloid-related Imaging Abnormality (ARIA),
-hemorrhage /hemosiderin deposition (ARIA-H) or presence of ARIA-E (edema/effusions)
